



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A01N 37/18, C12P 21/06, C07K 1/00, 14/00, 17/00	A1	(11) International Publication Number: WO 96/31122 (43) International Publication Date: 10 October 1996 (10.10.96)
(21) International Application Number: PCT/US96/04294 (22) International Filing Date: 2 April 1996 (02.04.96) (30) Priority Data: 08/416,257 4 April 1995 (04.04.95) US (60) Parent Application or Grant (63) Related by Continuation US 08/416,257 (CON) Filed on 4 April 1995 (04.04.95) (71) Applicant (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DIXON, Eric, P. [US/US]; 4246 Bay Leaf Circle, Indianapolis, IN 46237 (US). JOHNSTONE, Edward, M. [US/US]; 5129 East 69th Street, Indianapolis, IN 46220 (US). LITTLE, Sheila, P. [US/US]; 4480 North Meridian Street, Indianapolis, IN 46208 (US). (74) Agents: BLALOCK, Donna, K. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: AMYLOID PRECURSOR PROTEIN PROTEASE (57) Abstract <p>This invention describes a novel human amyloid precursor protein protease. This invention also encompasses nucleic acids encoding this protease, or a fragment thereof, as well as methods employing this protease and the nucleic acid compounds.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

AMYLOID PRECURSOR PROTEIN PROTEASE

Alzheimer's disease is a degenerative disorder of
5 the human brain. Clinically, it appears as a progressive
dementia. Its histopathology is characterized by
degeneration of neurons, gliosis, and the abnormal deposition
of proteins in the brain. Proteinaceous deposits (called
"amyloid") appear as neurofibrillary tangles, amyloid plaque
10 cores, and amyloid of the congophilic angiopathy. [For a
review, see, D.J. Selkoe, Neuron, 6:487-498 (1991)]

While there is no general agreement as to the
chemical nature of neurofibrillary tangles, the major
constituent of both the amyloid plaque cores and the amyloid
15 of the congophilic angiopathy has been shown to be a 4500
Dalton protein originally termed β -protein or amyloid A4.
Throughout this document this protein is referred to as β -
amyloid peptide or protein.

β -Amyloid peptide is proteolytically derived from a
20 transmembrane protein, the amyloid precursor protein.
Different splice forms of the amyloid precursor protein are
encoded by a widely expressed gene. see, e.g., K. Beyreuther
and B. Müller-Hill, Annual Reviews in Biochemistry, 58:287-
307 (1989). The most abundant form of amyloid precursor
25 protein found in the human brain contains 695 amino acid
residues and is designated as APP 695. At least three other
forms do exist, however, these being given the names APP 714,
APP 751, and APP 770. Tanzi, et al., Nature (London), 351:328
(1988); Ponte, et al., Nature (London), 331:525 (1988);
30 Kitaguchi, et al., Nature (London), 331:530 (1988).

The different length isoforms arise from
alternative splicing from a single amyloid precursor protein
gene located on chromosome 21. Goldgaber, et al., Science,
235:877 (1987).

35 APP 751 and APP 770 contain a 56 amino acid Kunitz
inhibitor domain, which shares 40% homology with bovine
pancreatic trypsin inhibitor. Both of these forms of amyloid

- 2 -

pancreatic trypsin inhibitor. Both of these forms of amyloid precursor protein have protease inhibitory activity. Kitaguchi, et al., supra.

Studies have also been performed to examine if changes in the relative amounts of the different forms of amyloid precursor protein are responsible for amyloid accumulation. The results of such studies have been equally confusing, but have generally supported the conclusion that the relative expression levels of the Kunitz domain containing amyloid precursor proteins are elevated in Alzheimer's disease. Johnson, et al., Science, 248:854 (1990).

Recent studies have shown that amyloid precursor protein fragments extending from the N-terminus of β -amyloid peptide to the C-terminus of the full length amyloid precursor protein (the "C-100 fragment") are also capable of aggregation in vitro and in transfected cells. Dyrks, et al., EMBO Journal, 7:949 (1988); Wolf, et al., EMBO Journal, 9:2079 (1990).

β -amyloid peptide consists, in its longest forms, of 42 or 43 amino acid residues. J. Kang, et al., Nature (London), 325:733-736 (1987). These peptides, however, vary as to their amino-termini. C. Hilbich, et al., Journal of Molecular Biology, 218:149-163 (1991).

The enzymes responsible for the normal, non-pathological processing of amyloid precursor protein have been termed "secretases". It is believed that the net pathological accumulation of β -amyloid peptide is controlled by the relative activities of the pathologic and physiologic pathways of amyloid precursor protein.

Because senile plaques are invariably surrounded by dystrophic neurites, it was proposed early that β -amyloid peptide is involved in the loss of neuronal cells that occurs in Alzheimer's disease. Bruce Yankner and co-workers were the first to demonstrate that synthetic β -amyloid peptide could be neurotoxic in vitro and in vivo. B.A. Yankner, et al., Science, 245:417 (1989); See, also, N.W. Kowall, et al.,

- 3 -

Proceedings of the National Academy of Sciences, U.S.A.,
88:7247 (1991).

While many of the peptides which result from the processing of amyloid precursor protein have been identified, the proteases responsible for this processing remain unidentified for the most part.

In addition to Alzheimer's disease, Down's syndrome is also characterized by an accumulation of β -amyloid peptide. In patients suffering from Down's syndrome the β -amyloid peptide is the primary constituent of senile plaques and cerebrovascular deposits.

Because of the debilitating effects of Alzheimer's disease, Down's syndrome, and these other conditions associated with amyloidogenic peptides and proteins there continues to exist a need for effective treatments. This invention provides a novel serine protease which is believed to be involved in the processing or clearance of amyloid precursor protein to form β -amyloid peptide. This protease, therefore, is useful in the design and testing of compounds having utility in the treatment or prevention of a condition associated with β -amyloid peptide, especially Alzheimer's Disease.

This invention provides an isolated amino acid compound useful as a human amyloid precursor protein protease, said compound comprising the amino acid sequence

	Met	Ala	Arg	Ser	Leu	Leu	Leu	Pro	Leu	Gln	Ile	Leu	Leu	Leu	Ser	Leu	
	1				5					10					15		
30	Ala	Leu	Glu	Thr	Ala	Gly	Glu	Glu	Ala	Gln	Gly	Asp	Lys	Ile	Ile	Asp	
				20					25					30			
	Gly	Ala	Pro	Cys	Ala	Arg	Gly	Ser	His	Pro	Trp	Gln	Val	Ala	Leu	Leu	
			35					40					45				
35	Ser	Gly	Asn	Gln	Leu	His	Cys	Gly	Gly	Val	Leu	Val	Asn	Glu	Arg	Trp	
		50					55					60					
40	Val	Leu	Thr	Ala	Ala	His	Cys	Lys	Met	Asn	Glu	Tyr	Thr	Val	His	Leu	
	65					70					75					80	

- 4 -

Gly Ser Asp Thr Leu Gly Asp Arg Arg Ala Gln Arg Ile Lys Ala Ser
 85 90 95
 Lys Ser Phe Arg His Pro Gly Tyr Ser Thr Gln Thr His Val Asn Asp
 5 100 105 110
 Leu Met Leu Val Lys Leu Asn Ser Gln Ala Arg Leu Ser Ser Met Val
 115 120 125
 10 Lys Lys Val Arg Leu Pro Ser Arg Cys Glu Pro Pro Gly Thr Thr Cys
 130 135 140
 Thr Val Ser Gly Trp Gly Thr Thr Thr Ser Pro Asp Val Thr Phe Pro
 15 145 150 155 160
 Ser Asp Leu Met Cys Val Asp Val Lys Leu Ile Ser Pro Gln Asp Cys
 165 170 175
 20 Thr Lys Val Tyr Lys Asp Leu Leu Glu Asn Ser Met Leu Cys Ala Gly
 180 185 190
 Ile Pro Asp Ser Lys Lys Asn Ala Cys Asn Gly Asp Ser Gly Gly Pro
 195 200 205
 25 Leu Val Cys Arg Gly Thr Leu Gln Gly Leu Val Ser Trp Gly Thr Phe
 210 215 220
 Pro Cys Gly Gln Pro Asn Asp Pro Gly Val Tyr Thr Gln Val Cys Lys
 30 225 230 235 240
 Phe Thr Lys Trp Ile Asn Asp Thr Met Lys Lys His Arg
 245 250

hereinafter designated as SEQ ID NO:2.

35

The invention also provides an isolated nucleic acid compound that comprises a nucleic acid sequence which encodes for the amino acid compounds provided. Particularly this invention provides the isolated nucleic acid compound
 40 having the sequence

GAATCCCGGT TTTT TTTT TGAGGGTTT GTGTTTCTTT ATTTGTTTTG GTTTTAGGTC 60
 TTTACCAATT TGATTGGTTT ATCAACAGGG CATGAGGTTT AAATATATCT TTGAGGAAAG 120
 45 GTAAAGTCAA ATTTGACTTC ATAGGTCATC GCGCTCCTCA CTCCTGTGCA TTTTCTGTTG 180
 GAAGCACACA GTTAATTAAC TCAGTGTGGC GTTAGCGATG CTTTTTCATG GTGTCATTTA 240
 50 TCCACTTGGT GAACTTGCAG ACTTGAGTGT AGACTCCTGG GTCATTGGGT TGGCCGCAAG 300

- 5 -

GGAAAGTTCC CCAGGACACC AGACCTTGCA GGGTACCTCT GCACACCAAC GGTCCCCCTG 360
AGTCACCATT GCAGGCGTTT TTCTTGAGT CGGGGATGCC AGCGCACAGC ATGGAATTTT 420
5 CCAGTAAGTC CTTGTAAACC TTCGTGCAGT CCTGGGGGGA GATGAGCTTG ACATCCACGC 480
ACATGAGGTC AGAGGGAAAG GTCACATCTG GGCTCGTGGT AGTGCCCCAG CCGGAGACAG 540
TACAGGTGGT TCCAGGGGGT TCGCAGCGGG AGGGCAGCCT GACTTTCTTC ACCATGGATG 600
10 ACAGCCTGGC CTGGCTATTG AGCTTCACGA GCATGAGGTC ATTAACATGG GTCTGTGTGG 660
AGTAGCCGGG GTGGCGGAAT GACTTCGAGG CCTTGATCCT CTGAGCTCTC CTGTCGCCCCA 720
15 GCGTATCACT GCCCAGGTGC ACGGTGTACT CATTCACTT GCAGTGGGCG GCAGTGAGCA 780
CCCAGCGCTC ATTGACCAGG ACGCCTCCGC AGTGGAGCTG ATTGCCACTG AGCAGGGCCA 840
CCTGCCATGG GTGGGAGCCT CTGTCACATG GGGCGCCATC AATAATCTTG TCACCCTGGG 900
20 CTTCTTCTCC TGCAGTTTCC AAGGCTAAGG ATAGCAGTAA GATCTGCAGG GGCAGGAGAA 960
GGGATCTTGC CATGGTGCCC TGCTGAGCCG CTCAGGGGCT GCCAGGCGAG GAAGGGCCTC 1020
25 TCCTGCTGGA GCTCGAGAGG ATCTGATGTG ATCCAAGTTC CGACTTGGGC TGGCACACAC 1080
CGGAATTCC 1089

which is hereinafter designated as SEQ ID NO:1.

30

This invention also provides recombinant nucleic acid vectors comprising nucleic acids encoding SEQ ID NO:2. This invention also encompasses recombinant DNA vectors which comprise the isolated DNA sequence which is SEQ ID NO:1.

35

This invention also provides assays for determining protein regions which are susceptible to cleavage by the human amyloid precursor protein proteases of the present invention.

40

In further embodiments this invention provides assays for determining the efficacy and adverse reaction profile of agents useful in the treatment or prevention of disorders associated with an excess or deficiency in the amount of human amyloid precursor protein protease present.

45

- 6 -

The terms and abbreviations used in this document have their normal meanings unless otherwise designated. For example "°C" refers to degrees Celsius; "N" refers to normal or normality; "mmole" refers to millimole or millimoles; "g" refers to gram or grams; "ml" means milliliter or milliliters; "M" refers to molar or molarity; "µg" refers to microgram or micrograms; and "µl" refers to microliter or microliters.

All nucleic acid sequences, unless otherwise designated, are written in the direction from the 5' end to the 3' end, frequently referred to as "5' to 3'".

All amino acid or protein sequences, unless otherwise designated, are written commencing with the amino terminus ("N-terminus") and concluding with the carboxy terminus ("C-terminus").

"Base pair" or "bp" as used herein refers to DNA or RNA. The abbreviations A, C, G, and T correspond to the 5'-monophosphate forms of the deoxyribonucleosides (deoxy)adenine, (deoxy)cytidine, (deoxy)guanine, and (deoxy)thymine, respectively, when they occur in DNA molecules. The abbreviations U, C, G, and T correspond to the 5'-monophosphate forms of the ribonucleosides uracil, cytidine, guanine, and thymine, respectively when they occur in RNA molecules. In double stranded DNA, base pair may refer to a partnership of A with T or C with G. In a DNA/RNA, heteroduplex base pair may refer to a partnership of A with U or C with G. (See the definition of "complementary", infra.)

The terms "digestion" or "restriction" of DNA refers to the catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA ("sequence-specific endonucleases"). The various restriction enzymes used herein are commercially available and their reaction conditions, cofactors, and other requirements were used as would be known to one of ordinary skill in the art. Appropriate buffers and substrate amounts

- 7 -

for particular restriction enzymes are specified by the manufacturer or can be readily found in the literature.

"Ligation" refers to the process of forming phosphodiester bonds between two double stranded nucleic acid fragments (T. Maniatis, et al., MOLECULAR CLONING: A LABORATORY MANUAL, 1982, p. 146). Unless otherwise provided, ligation may be accomplished using known buffers and conditions with a DNA ligase, such as T4 DNA ligase.

The term "plasmid" refers to an extrachromosomal (usually) self-replicating genetic element. Plasmids are generally designated by a lower case "p" preceded and/or followed by letters and/or numbers. The starting plasmids herein are either commercially available, publicly available on an unrestricted basis, or can be constructed from available plasmids in accordance with published procedures. In addition, equivalent plasmids to those described are known in the art and will be apparent to the ordinarily skilled artisan.

The term "reading frame" means the nucleotide sequence from which translation occurs "read" in triplets by the translational apparatus of transfer RNA (tRNA) and ribosomes and associated factors, each triplet corresponding to a particular amino acid. A base pair insertion or deletion (termed a frameshift mutation) may result in two different proteins being coded for by the same DNA segment. To insure against this, the triplet codons corresponding to the desired polypeptide must be aligned in multiples of three from the initiation codon, i.e. the correct "reading frame" being maintained.

"Recombinant DNA cloning vector" as used herein refers to any autonomously replicating agent, including, but not limited to, plasmids and phages, comprising a DNA molecule to which one or more additional DNA segments can or have been added.

The term "recombinant DNA expression vector" as used herein refers to any recombinant DNA cloning vector in which a promoter has been incorporated.

- 8 -

The term "expression vector system" as used herein refers to a recombinant DNA expression vector in combination with one or more trans-acting factors that specifically influence transcription, stability, or replication of the recombinant DNA expression vector. The trans-acting factor may be expressed from a co-transfected plasmid, virus, or other extrachromosomal element, or may be expressed from a gene integrated within the chromosome.

"Transcription" as used herein refers to the process whereby information contained in a nucleotide sequence of DNA is transferred to a complementary RNA sequence.

The term "transfection" as used herein refers to the taking up of an expression vector by a host cell whether or not any coding sequences are in fact expressed. Numerous methods of transfection are known to the ordinarily skilled artisan, for example, calcium phosphate co-precipitation, and electroporation. Successful transfection is generally recognized when any indication of the operation of this vector occurs within the host cell.

The term "transformation" as used herein means the introduction of DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integration. Methods of transforming bacterial and eukaryotic hosts are well known in the art, many of which methods, such as nuclear injection, protoplast fusion or by calcium treatment using calcium chloride are summarized in J. Sambrook, et al., MOLECULAR CLONING: A LABORATORY MANUAL, (1989).

The term "translation" as used herein refers to the process whereby the genetic information of messenger RNA is used to specify and direct the synthesis of a polypeptide chain.

The term "vector" as used herein refers to a nucleic acid compound used for the transformation of cells in gene manipulation bearing polynucleotide sequences corresponding to appropriate protein molecules which when combined with appropriate control sequences confer specific

- 9 -

properties on the host cell to be transformed. Plasmids, viruses, and bacteriophage are suitable vectors. Artificial vectors are constructed by cutting and joining DNA molecules from different sources using restriction enzymes and ligases.

- 5 The term "vector" as used herein includes Recombinant DNA cloning vectors and Recombinant DNA expression vectors.

The terms "complementary" or "complementarity" as used herein refers to pair of bases, purines and pyrimidines, that associate through hydrogen bonding in double stranded
10 nucleic acid. The following base pairs are complementary: guanine and cytosine; adenine and thymine; and adenine and uracil.

The term "hybridization" as used herein refers to a process in which a strand of nucleic acid joins with a
15 complementary strand through base pairing. The conditions employed in the hybridization of two non-identical, but very similar, complementary nucleic acids varies with the degree of complementarity of the two strands and the length of the strands. Such techniques and conditions are well known to
20 practitioners in this field.

"Isolated amino acid sequence" refers to any amino acid sequence, however constructed or synthesized, which is locationally distinct from the naturally occurring sequence.

"Isolated DNA compound" refers to any DNA sequence,
25 however constructed or synthesized, which is locationally distinct from its natural location in genomic DNA.

"Isolated nucleic acid compound" refers to any RNA or DNA sequence, however constructed or synthesized, which is locationally distinct from its natural location.

30 A "primer" is a nucleic acid fragment which functions as an initiating substrate for enzymatic or synthetic elongation.

The term "promoter" refers to a DNA sequence which directs transcription of DNA to RNA.

35 A "probe" as used herein is a nucleic acid compound or a fragment thereof which hybridizes with a nucleic acid compound which encodes either the entire sequence SEQ ID

- 10 -

NO:2, a sequence complementary to SEQ ID NO:2, or a part thereof.

The term "stringency" refers to a set of hybridization conditions which may be varied in order to vary the degree of nucleic acid affinity for other nucleic acid. (See the definition of "hybridization", supra.)

The term "PCR" as used herein refers to the widely-known polymerase chain reaction employing a thermally-stable polymerase.

This invention provides the protein of SEQ ID NO:2, a human amyloid precursor protein. This protease is believed to be involved in the maturation of human amyloid precursor protein, especially that route of maturation which results in the formation of β -amyloid peptide.

Skilled artisans will recognize that the proteins of the present invention can be synthesized by a number of different methods. All of the amino acid compounds of the invention can be made by chemical methods well known in the art, including solid phase peptide synthesis, or recombinant methods. Both methods are described in U.S. Patent 4,617,149, herein incorporated by reference.

The principles of solid phase chemical synthesis of polypeptides are well known in the art and may be found in general texts in the area. See, e.g., H. Dugas and C. Penney, BIOORGANIC CHEMISTRY, (1981) Springer-Verlag, New York, pgs. 54-92. For examples, peptides may be synthesized by solid-phase methodology utilizing an Applied Biosystems 430A peptide synthesizer (commercially available from Applied Biosystems, Foster City California) and synthesis cycles supplied by Applied Biosystems. Protected amino acids, such as *t*-butoxycarbonyl-protected amino acids, and other reagents are commercially available from many chemical supply houses.

Sequential *t*-butoxycarbonyl chemistry using double couple protocols are applied to the starting *p*-methyl benzhydryl amine resins for the production of C-terminal carboxamides. For the production of C-terminal acids, the corresponding pyridine-2-aldoxime methiodide resin is used.

- 11 -

Asparagine, glutamine, and arginine are coupled using preformed hydroxy benzotriazole esters. The following side chain protection may be used:

5 Arg, Tosyl
 Asp, cyclohexyl
 Glu, cyclohexyl
 Ser, Benzyl
 Thr, Benzyl
 Tyr, 4-bromo carbobenzoxy

10 Removal of the t-butoxycarbonyl moiety (deprotection) may be accomplished using standard deprotection procedures, such as with trifluoroacetic acid (TFA) in methylene chloride. Following completion of the synthesis, the peptides may be deprotected and cleaved from
15 the resin with anhydrous hydrogen fluoride containing 10% m-cresol. Cleavage of the side chain protecting group(s) and of the peptide from the resin is carried out at zero degrees Celsius or below, preferably at about -20°C for thirty minutes followed by thirty minutes at 0°C.

20 After removal of the hydrogen fluoride, the peptide/resin is washed with ether, and the peptide extracted with glacial acetic acid and then lyophilized. Purification is accomplished by size-exclusion chromatography on a Sephadex G-10 (Pharmacia) column in 10% acetic acid.

25 The proteins of the present invention may also be produced by recombinant methods. Recombinant methods are preferred if a high yield is desired. A general method for the construction of any desired DNA sequence is provided in J. Brown, et al., Methods in Enzymology, 68:109 (1979). See
30 also, J. Sambrook, et al., supra.

The basic steps in the recombinant production of desired proteins are:

35 a) construction of a synthetic or semi-synthetic DNA encoding the protein of interest;

- 12 -

- 5 b) integrating said DNA into an expression
vector in a manner suitable for the expression
of the protein of interest, either alone or as
a fusion protein;
- c) transforming an appropriate eukaryotic or
prokaryotic host cell with said expression
vector,
- 10 d) culturing said transformed or transfected
host cell in a manner to express the protein
of interest; and
- e) recovering and purifying the
15 recombinantly produced protein of interest.

 In general, prokaryotes are used for cloning of DNA
sequences in constructing the vectors of this invention.
Prokaryotes may also be employed in the production of the
20 protein of interest. For example, the Escherichia coli K12
strain 294 (ATCC No. 31446) is particularly useful for the
prokaryotic expression of foreign proteins. Other strains of
E. coli which may be used (and their relevant genotypes)
include the following.

25

<u>Strain</u>	<u>Genotype</u>
DH5 α	F ⁻ (ϕ 80dIacZ Δ M15), Δ (lacZYA-argF)U169 supE44, λ^{-} , hsdR17(r _F ⁻ , m _F ⁺), recA1, 30 endA1, gyrA96, thi-1, relA1
HB101	supE44, hsdS20(r _F ⁻ m _F ⁻), recA13, ara ⁻ 14, proA2 lacY1, galK2, rpsL20, xyl-5, 35 mtl-1, mcrB, mrr

- 13 -

- JM109 recA1, el4⁻(mcrA), supE44, endA1,
 hsdR17(r_K⁻, m_K⁺), gyrA96, relA1, thi-
 1, Δ(lac-proAB), F'[traD36, proAB+
 lacI^q, lacZΔM15]
- 5 RR1 supE44, hsdS20(r_S⁻ m_S⁻), ara-14 proA2,
 lacY1, galK2, rpsL20, xyl-5, mtl-5
- χ1776 F⁻, ton, A53, dapD8, minA1, supE42
 10 (glnV42), Δ(gal-uvrB)40, minB2, rfb-
 2, gyrA25, thyA142, oms-2, metC65,
 oms-1, Δ(bioH-asd)29, cycB2, cycA1,
 hsdR2, λ⁻
- 15 294 endA, thi⁻, hsr⁻, hsm_K⁺ (U.S. Patent
 4,366,246)

 These strains are all commercially available from
 suppliers such as: Bethesda Research Laboratories,
 20 Gaithersburg, Maryland 20877 and Stratagene Cloning Systems,
 La Jolla, California 92037; or are readily available to the
 public from sources such as the American Type Culture
 Collection, 12301 Parklawn Drive, Rockville, Maryland, 10852-
 1776.

25 Except where otherwise noted, these bacterial
 strains can be used interchangeably. The genotypes listed
 are illustrative of many of the desired characteristics for
 choosing a bacterial host and are not meant to limit the
 invention in any way. The genotype designations are in
 30 accordance with standard nomenclature. See, for example, J.
 Sambrook, et al., supra.

 In addition to the strains of E. coli discussed
supra, bacilli such as Bacillus subtilis, other
 enterobacteriaceae such as Salmonella typhimurium or Serratia
 35 marcescans, and various Pseudomonas species may be used. In
 addition to these gram-negative bacteria, other bacteria,
 especially Streptomyces, spp., may be employed in the

- 14 -

prokaryotic cloning and expression of the proteins of this invention.

Promoters suitable for use with prokaryotic hosts include the β -lactamase [vector pGX2907 (ATCC 39344) contains the replicon and β -lactamase gene] and lactose promoter systems [Chang *et al.*, Nature (London), 275:615 (1978); and Goeddel *et al.*, Nature (London), 281:544 (1979)], alkaline phosphatase, the tryptophan (trp) promoter system [vector pATH1 (ATCC 37695) is designed to facilitate expression of an open reading frame as a trpE fusion protein under control of the trp promoter] and hybrid promoters such as the tac promoter (isolatable from plasmid pDR540 ATCC-37282). However, other functional bacterial promoters, whose nucleotide sequences are generally known, enable one of skill in the art to ligate them to DNA encoding the proteins of the instant invention using linkers or adapters to supply any required restriction sites. Promoters for use in bacterial systems also will contain a Shine-Dalgarno sequence operably linked to the DNA encoding the desired polypeptides. These examples are illustrative rather than limiting.

The proteins of this invention may be synthesized either by direct expression or as a fusion protein comprising the protein of interest as a translational fusion with another protein or peptide which may be removable by enzymatic or chemical cleavage. It is often observed in the production of certain peptides in recombinant systems that expression as a fusion protein prolongs the lifespan, increases the yield of the desired peptide, or provides a convenient means of purifying the protein of interest. A variety of peptidases (e.g. trypsin) which cleave a polypeptide at specific sites or digest the peptides from the amino or carboxy termini (e.g. diaminopeptidase) of the peptide chain are known. Furthermore, particular chemicals (e.g. cyanogen bromide) will cleave a polypeptide chain at specific sites. The skilled artisan will appreciate the modifications necessary to the amino acid sequence (and synthetic or semi-synthetic coding sequence if recombinant

- 15 -

means are employed) to incorporate site-specific internal cleavage sites. See e.g., P. Carter, "Site Specific Proteolysis of Fusion Proteins", Chapter 13 in PROTEIN PURIFICATION: FROM MOLECULAR MECHANISMS TO LARGE SCALE PROCESSES, American Chemical Society, Washington, D.C. (1990).

In addition to cloning and expressing the genes of interest in the prokaryotic systems discussed above, the proteins of the present invention may also be produced in eukaryotic systems. The present invention is not limited to use in a particular eukaryotic host cell. A variety of eukaryotic host cells are available from depositories such as the American Type Culture Collection (ATCC) and are suitable for use with the vectors of the present invention. The choice of a particular host cell depends to some extent on the particular expression vector used to drive expression of the human glutamate receptor-encoding nucleic acids of the present invention. Exemplary host cells suitable for use in the present invention are listed in Table I

Table I

Host Cell	Origin	Source
HepG-2	Human Liver Hepatoblastoma	ATCC HB 8065
CV-1	African Green Monkey Kidney	ATCC CCL 70
LLC-MK ₂	Rhesus Monkey Kidney	ATCC CCL 7
3T3	Mouse Embryo Fibroblasts	ATCC CCL 92
CHO-K1	Chinese Hamster Ovary	ATCC CCL 61
HeLa	Human Cervix Epitheloid	ATCC CCL 2
RPMI8226	Human Myeloma	ATCC CCL 155
H4IIEC3	Rat Hepatoma	ATCC CCL 1600
C127I	Mouse Fibroblast	ATCC CCL 1616
HS-Sultan	Human Plasma Cell Plasmocytoma	ATCC CCL 1484
293	Human Embryonal Kidney	ATCC CRL 1573
BHK-21	Baby Hamster Kidney	ATCC CCL 10

- 16 -

An especially preferred cell line employed in this invention is the widely available cell line AV12-664 (hereinafter "AV12"). This cell line is available from the American Type Culture Collection under the accession number
5 ATCC CRL 9595. The AV12 cell line was constructed by injecting a Syrian hamster in the scruff of the neck with human adenovirus 12 and isolating cells from the resulting tumor.

A wide variety of vectors, some of which are
10 discussed below, exists for the transformation of such mammalian host cells, but the specific vectors described herein are in no way intended to limit the scope of the present invention.

The pSV2-type vectors comprise segments of the
15 simian virus 40 (SV40) genome that constitute a defined eukaryotic transcription unit-promoter, intervening sequence, and polyadenylation site. In the absence of the SV40 T antigen, the plasmid pSV2-type vectors transform mammalian and other eukaryotic host cells by integrating into the host
20 cell chromosomal DNA. A large number of plasmid pSV2-type vectors have been constructed, such as plasmid pSV2-gpt, pSV2-neo, pSV2-dhfr, pSV2-hyg, and pSV2- β -globin, in which the SV40 promoter drives transcription of an inserted gene. These vectors are suitable for use with the coding sequences
25 of the present invention and are widely available from sources such as the ATCC or the Northern Regional Research Laboratory (NRRL), 1815 N. University Street, Peoria, Illinois, 61604.

The plasmid pSV2-dhfr (ATCC 37146) comprises a
30 murine dihydrofolate reductase (dhfr) gene under the control of the SV40 early promoter. Under the appropriate conditions, the dhfr gene is known to be amplified, or copied, in the host chromosome. This amplification can result in the amplification of closely-associated DNA
35 sequences and can, therefore, be used to increase production of a protein of interest. See, e.g., J. Schimke, Cell, 35:705-713 (1984).

- 17 -

Plasmids constructed for expression of the proteins of the present invention in mammalian and other eukaryotic host cells can utilize a wide variety of promoters. The present invention is in no way limited to the use of the particular promoters exemplified herein. Promoters such as the SV40 late promoter, promoters from eukaryotic genes, such as, for example, the estrogen-inducible chicken ovalbumin gene, the interferon genes, the gluco-corticoid-inducible tyrosine aminotransferase gene, and the thymidine kinase gene, and the major early and late adenovirus genes can be readily isolated and modified to express the genes of the present invention. Eukaryotic promoters can also be used in tandem to drive expression of a coding sequence of this invention. Furthermore, a large number of retroviruses are known that infect a wide range of eukaryotic host cells. The long terminal repeats in the retroviral DNA frequently encode functional promoters and, therefore, may be used to drive expression of the nucleic acids of the present invention.

Plasmid pRSVcat (ATCC 37152) comprises portions of a long terminal repeat of the Rous Sarcoma virus, a virus known to infect chickens and other host cells. This long terminal repeat contains a promoter which is suitable for use in the vectors of this invention. H. Gorman, et al., Proceedings of the National Academy of Sciences (USA), 79:6777 (1982). The plasmid pMSVi (NRRL B-15929) comprises the long terminal repeats of the Murine Sarcoma virus, a virus known to infect mouse and other host cells. The mouse metallothionein promoter has also been well characterized for use in eukaryotic host cells and is suitable for use in the expression of the nucleic acids of the present invention. The mouse metallothionein promoter is present in the plasmid pdBPV-MMTneo (ATCC 37224) which can serve as the starting material of other plasmids of the present invention.

An especially preferred expression vector system employs one of a series of vectors containing the BK enhancer, an enhancer derived from the BK virus, a human papovavirus. The most preferred such vector systems are

- 18 -

those which employ not only the BK enhancer but also the adenovirus-2-early region 1A (E1A) gene product. The E1A gene product (actually, the E1A gene produces two products, which are collectively referred to herein as "the E1A gene product") is an immediate-early gene product of adenovirus, a large DNA virus.

A most preferred expression vector employed in the present invention is the phd series of vectors which comprise a BK enhancer in tandem with the adenovirus late promoter to drive expression of useful products in eukaryotic host cells. The construction and method of using the phd plasmid, as well as related plasmids, are described in U.S. Patents 5,242,688, issued September 7, 1993, and 4,992,373, issued February 12, 1991, all of which are herein incorporated by reference.

Escherichia coli K12 GM48 cells harboring the plasmid phd are available as part of the permanent stock collection of the Northern Regional Research Laboratory under accession number NRRL B-18525. The plasmid may be isolated from this culture using standard techniques.

The plasmid phd contains a unique BclI site which may be utilized for the insertion of the gene encoding the protein of interest. The skilled artisan understands that linkers or adapters may be employed in cloning the gene of interest into this BclI site. A depiction of the plasmid phd is provided as Figure 2 of this document. The phd series of plasmids functions most efficiently when introduced into a host cell which produces the E1A gene product, cell lines such as AV12-664, 293 cells, and others, described supra.

An especially preferred vector employed in this invention uses a transcriptional regulatory region from cytomegalovirus. This vector (pRc/CMV) is commercially available (Invitrogen Corporation, San Diego, California) and is described in A. Akrigg, et al., Virus Research, 2:107-121 (1985). This vector contains a restriction endonuclease polylinker to allow rapid unidirectional insertion of the gene of interest.

- 19 -

Transformation of the mammalian cells can be performed by any of the known processes including, but not limited to, the protoplast fusion method, the calcium phosphate co-precipitation method, electroporation and the like. See, e.g., J. Sambrook, et al., supra, at 3:16.30-3:16.66.

Other routes of production are well known to skilled artisans. In addition to the plasmid discussed above, it is well known in the art that some viruses are also appropriate vectors. For example, the adenovirus, the adeno-associated virus, the vaccinia virus, the herpes virus, the baculovirus, and the rous sarcoma virus are useful. Such a method is described in U.S. Patent 4,775,624, herein incorporated by reference. Several alternate methods of expression are described in J. Sambrook, et al., supra, at 16.3-17.44.

In addition to prokaryotes and mammalian host cells, eukaryotic microbes such as yeast cultures may also be used. The imperfect fungus Saccharomyces cerevisiae, or common baker's yeast, is the most commonly used eukaryotic microorganism, although a number of other strains are commonly available. For expression in Saccharomyces sp., the plasmid YRp7 (ATCC-40053), for example, is commonly used. See, e.g., L. Stinchcomb, et al., Nature, 282:39 (1979); J. Kingsman et al., Gene, 7:141 (1979); S. Tschemper et al., Gene, 10:157 (1980). This plasmid already contains the trp gene which provides a selectable marker for a mutant strain of yeast lacking the ability to grow in tryptophan.

Suitable promoting sequences for use with yeast hosts include the promoters for 3-phosphoglycerate kinase [found on plasmid pAP12BD (ATCC 53231) and described in U.S. Patent No. 4,935,350, issued June 19, 1990, herein incorporated by reference] or other glycolytic enzymes such as enolase [found on plasmid pAC1 (ATCC 39532)], glyceraldehyde-3-phosphate dehydrogenase [derived from plasmid pHcGAPC1 (ATCC 57090, 57091)], hexokinase, pyruvate decarboxylase, phosphofructokinase, glucose-6-phosphate

- 20 -

isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phosphoglucose isomerase, and glucokinase, as well as the alcohol dehydrogenase and pyruvate decarboxylase genes of Zymomonas mobilis (United States Patent No. 5,000,000 issued March 19, 1991, herein incorporated by reference).

Other yeast promoters, which are inducible promoters, having the additional advantage of their transcription being controllable by varying growth conditions, are the promoter regions for alcohol dehydrogenase 2, isocytochrome C, acid phosphatase, degradative enzymes associated with nitrogen metabolism, metallothionein [contained on plasmid vector pCL28XhoLHBPV (ATCC 39475) and described in United States Patent No. 4,840,896, herein incorporated by reference], glyceraldehyde 3-phosphate dehydrogenase, and enzymes responsible for maltose and galactose [e.g. GAL1 found on plasmid pRY121 (ATCC 37658)] utilization. Suitable vectors and promoters for use in yeast expression are further described in R. Hitzeman et al., European Patent Publication No. 73,657A. Yeast enhancers such as the UAS Gal from Saccharomyces cerevisiae (found in conjunction with the CYC1 promoter on plasmid YEpsec--hI1beta ATCC 67024), also are advantageously used with yeast promoters.

Practitioners of this invention realize that, in addition to the above-mentioned expression systems, the cloned cDNA may also be employed in the production of transgenic animals in which a test mammal, usually a mouse, in which expression or overexpression of the proteins of the present invention can be assessed. The nucleic acids of the present invention may also be employed in the construction of "knockout" animals in which the expression of the native cognate of the gene is suppressed.

Skilled artisans also recognize that some alterations of SEQ ID NO:2 will fail to change the function of the amino acid compound. For instance, some hydrophobic amino acids may be exchanged for other hydrophobic amino

- 21 -

acids. Those altered amino acid compounds which confer substantially the same function in substantially the same manner as the exemplified amino acid compound are also encompassed within the present invention. Typical such conservative substitutions attempt to preserve the: (a) secondary or tertiary structure of the polypeptide backbone; (b) the charge or hydrophobicity of the residue; or (c) the bulk of the side chain. Some examples of such conservative substitutions of amino acids, resulting in the production of proteins which are functional equivalents of the protein of SEQ ID NO:2 are shown in Table II.

Table II

	Original Residue	Exemplary Substitutions
15	Ala	Ser, Gly
	Arg	Lys
	Asn	Gln, His
	Asp	Glu
	Cys	Ser
20	Gln	Asn
	Glu	Asp
	Gly	Pro, Ala
	His	Asn, Gln
	Ile	Leu, Val
25	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	Met, Leu, Gyr
	Ser	Thr
30	Thr	Ser
	Trp	Tyr
	Tyr	Trp, Phe
	Val	Ile, Leu

- 22 -

These substitutions may be introduced into the protein in a variety of ways, such as during the chemical synthesis or by chemical modification of an amino acid side chain after the protein has been prepared.

5 Alterations of the protein having a sequence which corresponds to the sequence of SEQ ID NO:2 may also be induced by alterations of the nucleic acid compounds which encodes these proteins. These mutations of the nucleic acid compound may be generated by either random mutagenesis
10 techniques, such as those techniques employing chemical mutagens, or by site-specific mutagenesis employing oligonucleotides. Those nucleic acid compounds which confer substantially the same function in substantially the same manner as the exemplified nucleic acid compounds are also
15 encompassed within the present invention.

Other embodiments of the present invention are nucleic acid compounds which comprise isolated nucleic acid sequences which encode SEQ ID NO:2. As skilled artisans will recognize, the amino acid compounds of the invention can be
20 encoded by a multitude of different nucleic acid sequences because most of the amino acids are encoded by more than one nucleic acid triplet due to the degeneracy of the amino acid code. Because these alternative nucleic acid sequences would encode the same amino acid sequences, the present invention
25 further comprises these alternate nucleic acid sequences.

The gene encoding the human amyloid precursor protein protease molecule may be produced using synthetic methodology. This synthesis of nucleic acids is well known in the art. See, e.g., E.L. Brown, R. Belagaje, M.J. Ryan,
30 and H.G. Khorana, Methods in Enzymology, 68:109-151 (1979). The DNA segments corresponding to the receptor gene are generated using conventional DNA synthesizing apparatus such as the Applied Biosystems Model 380A or 380B DNA synthesizers (commercially available from Applied Biosystems, Inc., 850
35 Lincoln Center Drive, Foster City, CA 94404) which employ phosphoramidite chemistry. In the alternative, the more traditional phosphotriester chemistry may be employed to

- 23 -

synthesize the nucleic acids of this invention. See, e.g.,
OLIGONUCLEOTIDE SYNTHESIS, A PRACTICAL APPROACH, (M.J. Gait, ed.,
1984).

The synthetic human amyloid precursor protein
5 protease gene may be designed to possess restriction
endonuclease cleavage sites at either end of the transcript
to facilitate isolation from and integration into expression
and amplification plasmids. The choice of restriction sites
are chosen so as to properly orient the coding sequence of
10 the receptor with control sequences to achieve proper in-
frame reading and expression of the hAPP protease molecule.
A variety of other such cleavage sites may be incorporated
depending on the particular plasmid constructs employed and
may be generated by techniques well known in the art.

15 In an alternative methodology, the desired DNA
sequences can be generated using the polymerase chain
reaction as described in U.S. Patent No. 4,889,818, which is
herein incorporated by reference.

In addition to the deoxyribonucleic acid of SEQ ID
20 NO:1, this invention also provides ribonucleic acids (RNA)
which comprise the RNA sequence

	GAAUCCGGU UUUUUUUUUU UGAGGGUUU GUGUUUCUUU AUUUGUUUG GUUUUAGGUC	60
25	UUUACCAAU UGAUUGGUU AUCAACAGG CAUGAGGUU AAAUAUAUCU UUGAGGAAAG	120
	GUAAAGUCAA AUUUGACUUC AUAGGUCAUC GCGGUCCUCA CUCCUGUGCA UUUUCUGUUG	180
	GAAGCACACA GUUAAUUAAC UCAGUGUGGC GUUAGCGAUG CUUUUUAUG GUGUCAUUUA	240
30	UCCACUUGGU GAACUUGCAG ACUUGAGUGU AGACUCCUGG GUCAUUGGGU UGGCCGCAAG	300
	GGAAAGUCC CCAGGACACC AGACCUUGCA GGGUACCUCU GCACACCAAC GGUCCCCUG	360
35	AGUCACCAU GCAGGCGUUU UUCUUGGAGU CGGGGAUGCC AGCGCACAGC AUGGAAUUUU	420
	CCAGUAAGUC CUUGUAAAACC UUCGUGCAGU CCUGGGGGGA GAUGAGCUUG ACAUCCACGC	480
	ACAUGAGGUC AGAGGGAAAG GUCACAUCUG GGCUCGUGGU AGUGCCCCAG CCGGAGACAG	540
40	UACAGGUGGU UCCAGGGGGU UCGCAGCGG AGGGCAGCCU GACUUUCUUC ACCAUGGAUG	600
	ACAGCCUGGC CUGGCUAUUG AGCUUCACGA GCAUGAGGUC AUUAACAUGG GUCUGUGUGG	660

- 24 -

	AGUAGCCGGG GUGGCGGAU GACUUCGAGG CCUUGAUCCU CUGAGCUCUC CUGUCGCCCA	720
	GCGUAUCACU GCCCAGGUGC ACGGUGUACU CAUUCAUCUU GCAGUGGGCG GCAGUGAGCA	780
5	CCCAGCGCUC AUUGACCAGG ACGCCUCCGC AGUGGAGCUG AUUGCCACUG AGCAGGGCCA	840
	CCUGCCAUGG GUGGGAGCCU CUUGCACAUG GGGCGCCAUC AAUAAUCUUG UCACCCUGGG	900
10	CUUCUUCUCC UGCAGUUUCC AAGGCUAAGG AUAGCAGUAA GAUCUGCAGG GGCAGGAGAA	960
	GGGAUCUUGC CAUGGUGCCC UGCUGAGCCG CUCAGGGGCU GCCAGGCGAG GAAGGGCCUC	1020
	UCCUGCUGGA GCUCGAGAGG AUCUGAUGUG AUCCAAGUUC CGACUUGGGC UGGCACACAC	1080
15	CGGAAUUC	1089

hereinafter referred to as SEQ ID NO:3, or the complementary ribonucleic acid, or a fragment of either SEQ ID NO:3 or the complement thereof. The ribonucleic acids of the present invention may be prepared using the polynucleotide synthetic methods discussed supra or they may be prepared enzymatically using RNA polymerases to transcribe a DNA template.

The most preferred systems for preparing the ribonucleic acids of the present invention employ the RNA polymerase from the bacteriophage T7 or the bacteriophage SP6. Both of these RNA polymerases are highly specific and require the insertion of bacteriophage-specific sequences at the 5' end of the message to be read. See, J. Sambrook, et al., supra, at 18.82-18.84.

This invention also provides nucleic acids, RNA or DNA, which are complementary to SEQ ID NO:1 or SEQ ID NO:3.

The present invention also provides probes and primers useful for molecular biology techniques. A compound which encodes for SEQ ID NO:1, SEQ ID NO:3, a complementary sequence of either SEQ ID NO:1 or SEQ ID NO:3, or a fragment thereof, and which is at least 18 base pairs in length, and which will selectively hybridize to human genomic DNA or messenger RNA encoding a human glutamate receptor, is provided. Preferably, the 18 or more base pair compound is DNA.

- 25 -

The term "selectively hybridize" as used herein may refer to either of two situations. In the first such embodiment of this invention, the nucleic acid compounds described supra hybridize to a human amyloid precursor protein protease under more stringent hybridization conditions than these same nucleic acid compounds would hybridize to an analogous protease in another species, e.g. murine or primate. In the second such embodiment of this invention, these probes hybridize to the hAPP protease under more stringent hybridization conditions than other related compounds, including nucleic acid sequences encoding other serine proteases.

These probes and primers can be prepared enzymatically as described supra. In a most preferred embodiment these probes and primers are synthesized using chemical means as described supra. Probes and primers of defined structure may also be purchased commercially.

This invention also encompasses recombinant DNA cloning vectors and expression vectors comprising the nucleic acids of the present invention. Many of the vectors encompassed within this invention are described above. The preferred nucleic acid vectors are those which are DNA. The most preferred recombinant DNA vector comprises the isolated DNA sequence SEQ ID NO:1.

The nucleic acid compounds encoding the human amyloid precursor protein protease were prepared by probing messenger (mRNA) isolated from human brain tissue, superior frontal gyrus. The probes employed were designed from conserved regions in known serine proteases. One primer employed in this cloning contained the following sequence:

GTG(A/C)TGACAGCTGCCCACTG

which is hereinafter referred to as SEQ ID NO:7. Another primer sequence employed contained the following sequence:

CAGCT(G/T)CAGCAGCATGATGTC

- 26 -

which is hereinafter referred to as SEQ ID NO:8.

From the mRNA so isolated cDNA was prepared using standard commercially available kits and protocols. After
5 the synthesis of this first strand, multiple copies of this cDNA were prepared using PCR technology. The products of the PCR process were then electrophoretically separated on a Daiichi gel and those fragments having the expected were excised, and the DNA was extracted using standard techniques.

10 The full-length clone of the human amyloid precursor protein protease was then isolated from a commercially available human lung cDNA lambda gt10 library. The skilled practitioner understands that other readily available cDNA libraries may be used in the preparation of
15 the nucleotides of this invention. After the full-length clone was isolated, it was sequenced using standard techniques to give the nucleic acid sequences described in this invention.

The skilled artisan understands that the type of
20 cloning vector or expression vector employed depends upon the availability of appropriate restriction sites, the type of host cell in which the vector is to be transfected or transformed, the purpose of the transfection or transformation (e.g., transient expression in an oocyte
25 system, stable transformation as an extrachromosomal element, or integration into the host chromosome), the presence or absence of readily assayable markers (e.g., antibiotic resistance markers, metabolic markers, or the like), and the number of copies of the gene to be present in the cell.

30 The type of vector employed to carry the nucleic acids of the present invention may be RNA viruses, DNA viruses, lytic bacteriophages, lysogenic bacteriophages, stable bacteriophages, plasmids, viroids, and the like. The most preferred vectors of the present invention are those
35 derived from plasmids.

When preparing an expression vector the skilled artisan understands that there are many variables to be

- 27 -

considered. One such example is the use of a constitutive promoter, i.e. a promoter which is functional at all times, instead of a regulatable promoter which may be activated or inactivated by the artisan using heat, addition or removal of a nutrient, addition of an antibiotic, and the like. The practitioner also understands that the amount of nucleic acid or protein to be produced dictates, in part, the selection of the expression system. For experiments examining the amount of the protein expressed on the cell membrane or for experiments examining the biological function of an expressed membrane protein, for example, it may be unwise to employ an expression system which produces too much of the protein. The addition or subtraction of certain sequences, such as a signal sequence preceding the coding sequence, may be employed by the practitioner to influence localization of the resulting polypeptide. Such sequences added to or removed from the nucleic acid compounds of the present invention are encompassed within this invention.

A plasmid comprising the nucleic acids of the present invention is readily modified to construct expression vectors that produce human amyloid precursor protein protease in a variety of organisms, including, for example, E. coli, Sf9 (as host for baculovirus), Spodoptera and Saccharomyces. The current literature contains techniques for constructing AV12 expression vectors and for transforming AV12 host cells. United States Patent No. 4,992,373, herein incorporated by reference, is one of many references describing these techniques.

One of the most widely employed techniques for altering a nucleic acid sequence is by way of oligonucleotide-directed site-specific mutagenesis. B. Comack, CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, 8.01-8.5.9, (F. Ausubel, et al., eds. 1991). In this technique an oligonucleotide, whose sequence contains the mutation of interest, is synthesized as described supra. This oligonucleotide is then hybridized to a template containing the wild-type sequence. In a most preferred embodiment of

- 28 -

this technique, the template is a single-stranded template. Particularly preferred are plasmids which contain regions such as the fl intergenic region. This region allows the generation of single-stranded templates when a helper phage
5 is added to the culture harboring the "phagemid".

After the annealing of the oligonucleotide to the template, a DNA-dependent DNA polymerase is then used to synthesize the second strand from the oligonucleotide, complementary to the template DNA. The resulting product is
10 a heteroduplex molecule containing a mismatch due to the mutation in the oligonucleotide. After DNA replication by the host cell a mixture of two types of plasmid are present, the wild-type and the newly constructed mutant. This technique permits the introduction of convenient restriction
15 sites such that the coding sequence may be placed immediately adjacent to whichever transcriptional or translational regulatory elements are employed by the practitioner.

The construction protocols utilized for E. coli can be followed to construct analogous vectors for other
20 organisms, merely by substituting, if necessary, the appropriate regulatory elements using techniques well known to skilled artisans.

Host cells which harbor the nucleic acids provided by the present invention are also provided. A preferred host
25 cell is an Xenopus sp. oocyte which has been injected with RNA or DNA compounds of the present invention. Most preferred oocytes of the present invention are those which harbor a sense mRNA of the present invention. Other preferred host cells include AV12 and E. coli cells which
30 have been transfected and/or transformed with a vector which comprises a nucleic acid of the present invention.

The present invention also provides a method for constructing a recombinant host cell capable of expressing
SEQ ID NO:2, said method comprising transforming a host cell
35 with a recombinant DNA vector that comprises an isolated DNA sequence which encodes SEQ ID NO:2. The preferred host cell is AV12. The preferred vector for expression is one which

- 29 -

comprises SEQ ID NO:1. Another preferred host cell for this method is E. coli. An especially preferred expression vector in E. coli is one which comprises SEQ ID NO:1. Transformed host cells may be cultured under conditions well known to skilled artisans such that SEQ ID NO:2 is expressed, thereby producing human amyloid precursor protein protease in the recombinant host cell.

The ability of the human amyloid precursor protein protease to cleave the appropriate substrate is essential in the development of a multitude of indications. The development of agents which interfere or inhibit this cleavage is, therefore, important in the development of therapeutic agents effective in the treatment or prevention of conditions such as Alzheimer's Disease.

As used herein, the term "amyloid precursor protein substrate" or "APP substrate" refers to full length amyloid precursor protein, whether derived by isolation or purification from a biological source or by expression of a cloned gene encoding amyloid precursor protein or its analogs, and fragments of any such protein, including fragments obtained by digestion of the protein or a portion thereof, fragments obtained by expression of a gene coding for a portion of the amyloid precursor protein, and synthetic peptides having amino acid sequences corresponding to a portion of the amyloid precursor protein.

Amyloid precursor protein substrates for the assays of the present invention can be provided as a test reagent in a variety of forms. Although preferably derived from, or corresponding at least in part with the amino acid sequence of, APP 695, derivatives or analogs of other amyloid precursor protein isoforms are contemplated for use in the present method as well. APP 695 can be obtained by biochemical isolation or purification from natural sources such as described in Schubert, et al., Proceedings of the National Academy of Sciences (USA), 86:2066 (1989); or by expression of recombinant DNA clones encoding the protein or

- 30 -

a functional protein thereof. Knops, et al., Journal of Biological Chemistry, 266:7825 (1991).

The fragments of the amyloid precursor protein will comprise a sequence of amino acids sufficient for recognition and cleavage by the proteases of the present invention. Isolation of amyloid precursor protein from biological material usually will involve purification by conventional techniques such as chromatography, particularly affinity chromatography. Purified amyloid precursor protein or fragments thereof can be used to prepare monoclonal antibodies or polyclonal antibodies which can then be used in affinity purification according to conventional procedures.

Such an inhibition assay includes a method for determining whether a protein sequence is a functional substrate of the human amyloid precursor protein protease of the instant invention, said method comprising contacting a functional human amyloid precursor protein protease of the instant invention with said protein sequence, monitoring proteolysis activity by physically detectable means, and then identifying those substances which effect a chosen response.

A variety of convenient methods are applicable to the detection of proteolytic cleavage of the amyloid precursor protein substrate in the presence of a test sample. Several of the presently more preferred methods are described below, however, it will be recognized by the skilled worker in the field that many other methods can be applied to this step without departing from the inventive features thereof. In general, any method can be used for this purpose which is capable of detecting the occurrence of proteolytic cleavage of the amyloid precursor protein substrate. Such can be afforded by appropriate design of the amyloid precursor protein substrate such that cleavage produces a signal producing species, e.g., an optically responsive product such as a colored or fluorescent dye.

Another principal approach involves the sensitive detection of one or more cleavage products such as by immunoassay. Presently, such cleavage product is

- 31 -

preferentially a C-terminal fragment of the amyloid precursor protein substrate. Any fragment which appears upon incubation with the proteases of the present invention can be the object of detection.

5 The detection of one or more cleavage products characteristic of the pathologic proteolytic activity can be accomplished in many ways. One such method involves the procedure commonly known as the Western blot. Typically, after incubation of amyloid precursor protein with a protease
10 of the present invention, gel electrophoresis is performed to separate the components resulting in the reaction mixture. The separated protein components are then transferred to a solid matrix such as a nitrocellulose or nylon membrane.

 An antibody specific to a fragment characteristic
15 of amyloid precursor protein degradation is then reacted with the components fixed to the membrane and detected by addition of a secondary enzyme-labeled antibody conjugate. The location of the resulting bound conjugate is developed with a chromogenic substrate for the enzyme label.

20 A variety of immunoassay formats which are amenable to currently available test systems can also be applied to the detection of amyloid precursor protein fragments. Typically, the amyloid precursor protein substrate will incubated with a amyloid precursor protein protease of the
25 present invention. The resulting intact amyloid precursor protein is then rendered immobilized (such as by capture onto a solid phase), or alternatively, the amyloid precursor protein protease is incubated with an immobilized form of the amyloid precursor protein substrate. Proteolytic cleavage is
30 then detected by reacting the immobilized amyloid precursor protein substrate with an antibody reagent directed to a portion of the amyloid precursor protein substrate which is cleaved from the amyloid precursor protein substrate, or which defines the cleavage site.

35 Capture or immobilization of the amyloid precursor protein substrate can be accomplished in many ways. An antibody can be generated specific to an epitope of amyloid

- 32 -

precursor protein which is not on the cleavable fragment. Such an antibody can be immobilized and used to capture or immobilize intact amyloid precursor protein. Alternatively, a ligand or hapten can be covalently attached to amyloid precursor protein and a corresponding immobilized receptor or antibody can be used to capture or immobilize amyloid precursor protein. A typical ligand/receptor pair useful for this purpose is biotin/avidin. Examples of haptens useful for this purpose are fluorescein and digitoxigenin.

10 The solid phase on which amyloid precursor protein substrate is immobilized or captured can be composed of a variety of materials including microtiter plate wells, test tubes, strips, beads, particles, and the like. A particularly useful solid phase is magnetic or paramagnetic particles. Such particles can be derivatized to contain chemically active groups that can be coupled to a variety of compounds by simple chemical reactions. The particles can be cleared from suspension by bringing a magnet close to a vessel containing the particles. Thus, the particles can be washed repeatedly without cumbersome centrifugation or filtration, providing the basis for fully automating the assay procedure.

Labels for the primary or secondary antibody reagent can be selected from those well known in the art. 25 Some such labels are fluorescent or chemiluminescent labels, radioisotopes, and more preferably, enzymes for this purpose are alkaline phosphatase, peroxidase, and β -galactosidase. These enzymes are stable under a variety of conditions, have a high catalytic turnover rate, and can be detected using simple chromogenic substrates. 30

Proteolytic cleavage of the amyloid precursor protein substrate can also be detected by chromatographic techniques which will separate and then detect the amyloid precursor protein fragments. High performance liquid chromatography is particularly useful in this regard. In 35 applying this technique, a fluorescently tagged amyloid precursor protein is prepared. After incubation with the

- 33 -

protease of the present invention, the reaction mixture is applied to the chromatographic column and the differential rate of migration of fluorescent fragments versus intact amyloid precursor protein is observed.

5

The instant invention provides such a screening system useful for discovering agents which inhibit the cleavage of the human amyloid precursor protein proteases of the instant invention, said screening system comprising the steps of:

10

- a) isolating a human amyloid precursor protein protease;
- b) exposing said human amyloid precursor protein protease to a potential inhibitor of this protease;
- 15 c) introducing a suitable substrate; and
- d) quantifying the amount of cleavage of the substrate, relative to a control in which no potential inhibitor has been added.

20 This allows one to rapidly screen for inhibitors of the human amyloid precursor protein proteases of the instant invention. Utilization of the screening system described above provides a sensitive and rapid means to determine compounds which inhibit the proteases of the instant invention. This
25 screening system may also be adapted to automated procedures such as a Pandex® (Baxter-Dade Diagnostics) system allowing for efficient high-volume screening of potential therapeutic agents.

In such a screening protocol a human amyloid
30 precursor protein protease is prepared as elsewhere described herein, preferably using recombinant DNA technology. A sample of a test compound is then introduced to the reaction vessel containing the human amyloid precursor protein

- 34 -

protease followed by the addition of an appropriate substrate. In the alternative the substrate may be added simultaneously with the test compound.

5

Example 1

Purification of Human Amyloid Precursor Protein Protease by Ion-Exchange Chromatography

10 As the proteases of this invention are serine proteases may be purified by known means. See, e.g., European Patent Application 569,777 A2, published November 18, 1993.

(i) Sub-cellular fractionation. After expression
15 of a gene product of the present invention in an appropriate cell line, the pelleted cells are frozen and then thawed to lyse the cells. If further lysing is necessary the cell pellet may be suspended in a buffer such as 0.32 M sucrose and then homogenized in batches using a 100 ml Elvehjem glass
20 teflon potter (ten return strokes). The combined homogenate is centrifuged at 1000 g x 10 minutes.

The loose pellet is removed, re-homogenized and centrifuged as described above. The supernatant from each extraction is combined and centrifuged at 15,000 x g for 30
25 minutes. The resulting "P-2 pellet" is resuspended in 100 ml of ice-cold 0.32 M sucrose by vortexing and stored at -70°C. The supernatant from the last spin is centrifuged at 105,000 x g for 60 minutes to yield the supernatant or soluble fraction ("S") and the microsomal fraction ("M") which is
30 resuspended in 60 ml of 0.32 M sucrose. Both S and M are stored at -70°C.

(ii) Solubilization. The P-2 or M subfractions are solubilized by adjusting to the following conditions: 2%
35 (w/v) Triton X-100 containing 50 mM Tris HCl buffer, pH 7.5. After stirring at 4°C for 3.5 hours, the suspensions are centrifuged at 105,000 x g for 60 minutes. The following

- 35 -

final protein concentrations are used in solubilization: for P-2 (3.0 to 4.0 mg/ml); and for M (1.4 to 1.6 mg/ml). Solubilized supernatants are stored at -70°C for later use. The soluble fraction is not treated with detergent but rather is adjusted to 50 mM in Tris HCl, pH 7.5, by the addition of stock 1 M buffer.

(iii) Ion-exchange chromatography. Chromatography is performed using a Gilson gradient liquid chromatograph (model 305 and 306 pumps) equipped with a 50 ml Rheodyne stainless steel loop injector model 7125, and connected to a MONO Q HR 10/10 COLUMN™ (Pharmacia, Piscataway, New Jersey). Absorbance of column effluent is monitored at 280 nm.

Protein fractions of P-2, microsomal (M), or soluble (S) are loaded onto the column and equilibrated with 50 mM Tris HCl, pH 7.5 (conductivity 1.8 mU at 4°C) at a flow rate of 2 ml/minute. The column is then washed with an equilibration buffer until the A₂₈₀ nm in the eluent decreased to zero whereupon the column flow rate is increased to 4 ml/minute. Proteins are eluted as follows:

Solvents: A = 50 mM Tris HCl, pH 7.5
B = 50 mM Tris HCl, pH 7.5, 1 M NaCl

Program: 0-50% B over 70 minutes
hold 50% for 10 minutes
50-100% B over 10 minutes
hold 100% B for 10 minutes
re-equilibrate

Four milliliter fractions are collected throughout chromatography. The following protein loads are applied per column run:

P-2, 97 mg
S, 65 mg
M, 35 mg

In the initial studies, eluted fractions are monitored for A₂₈₀, total protein (Bradford assay), and

peptidase activity (as described infra). Pools made on the basis of peptidase activity are then prepared and then tested for their capacity to process CHO cell derived APP C-terminally.

10

Purification of Human Amyloid Precursor Protein Protease by Affinity Chromatography

20

25

30

In Vitro Assay for Human Amyloid Precursor Protein Protease
and Inhibitors Thereof

An in vitro assay is developed which enables high throughput screening of sequences which are capable of

- 37 -

serving as substrates for the protease of this invention. This high throughput assay also serves as an initial screen for compounds or compositions which have activity as inhibitors of the serine protease of this invention.

5 One preferred technology utilizes dansylated peptide substrates, in conjunction with subsequent detection of fluorescent peptide products by reverse phase high performance liquid chromatography, and post column fluorescence detection.

10 A fluorescently labeled dodeca-peptide substrate containing the same amino acid as observed surrounding the N-terminal region of the beta amyloid peptide sequence of human amyloid precursor protein is prepared by solid phase peptide synthesis using a commercially available peptide synthesizer, as described supra. Usually the peptides are cleaved and
15 deprotected in 90% trifluoroacetic acid, 4% thioanisole, 2% ethanedithiol, and 4% liquified phenol for about two hours at ambient temperatures. In order to avoid unrelated carboxy digestion due to non-specific exoproteases present in all but
20 the most highly purified protein preparations, a preferred substrate to employ is

N-dansyl-Ile-Ser-Glu-Val-Met-Asp-Ala-Glu-Phe-Arg-His-Asp-Asp-Asp-Asp

25 which is hereinafter identified as SEQ ID NO:9.

 Aliquots of column fractions described in Example 1 are incubated with 10 μ l of a reaction mixture so as to achieve the final component concentrations: test peptide of SEQ ID NO:9 (50 μ M), captopril (300 μ M), in a cocktail buffer
30 comprising 100 mM in each of MES, Tris, and acetate, pH 6.5.

 Incubation with ion-exchange fractions is performed at 37°C for about 24 hours, after which reactions are terminated by adjusting to 3% (v/v) final in trifluoroacetic acid.

35 HPLC analysis is performed using a binary solvent delivery system with an auto injector system. Fluorescence

- 38 -

detection is performed using a standard fluorometer (excitation at 310-410 nm, emission at 480-520 nm).

Aliquots of the above acidified incubation mixtures are injected onto a reverse phase chromatography column [Hypersil 5 μ M C18 column (100 x 4.6 mm) fitted with a C18 5 μ M guard column]. Isocratic separation is achieved using 100 mM sodium acetate buffer, pH 6.5, containing 27% (v/v) acetonitrile. Identification and quantification of resolved metabolites is made possible by comparison with the migration of synthetic peptide products, the structure of which are confirmed by PTC-amino acid analysis and fast atom bombardment mass spectrometry. One example of such a standard table is depicted in Table IV, infra.

Table IV

Peptide (N-dansyl-)	HPLC retention time (minutes)	Cleavage Site
ISEVKMDAEFRHDDDD	2.228 \pm 0.024	Substrate
ISEVKM	5.398 \pm 0.919	Met-Asp
ISEVK	3.413 \pm 0.004	Lys-Met
ISEV	2.692 \pm 0.003	Val-Lys
ISE	2.135 \pm 0.002	Glu-Val
IS	4.412 \pm 0.019	Ser-Glu

This table is derived from P. Tamburini, et al., European Patent Application Publication 0 569 777 A2, published November 18, 1993. In all the experiments the HPLC column is calibrated for daily variation in the retention times of the enzymatically-generated products by analysis of synthetic product standards in parallel with the experimental samples. Data for the proteolytic metabolite profile of individual ion-exchange fractions is collected using commercially available software.

Once the reaction conditions are established, the proteolytic assays are then repeated using varying amounts of

- 39 -

each of the test compounds believed to have proteolytic inhibitory activity. The results generated with these experiments, when compared with the controls in which no inhibitor is added, allow for the computation of an amount of a test compound effective in inhibiting 50% of the protease activity (IC₅₀).

Example 4

10 In Vivo Assay for Human Amyloid Precursor Protein Protease and Inhibitors Thereof

An in vivo assay, whereby specific sequences cleaved by the proteases of the present invention as well as compounds inhibiting the proteases of the present invention may be defined, was developed essentially as described in T.A. Smith and B.D. Kohorn, Proceedings of the National Academy of Sciences (USA), 88:5159-5162 (1991).

In another embodiment this invention provides a method for identifying, in a test sample, DNA homologous to a probe of the present invention, wherein the test nucleic acid is contacted with the probe under hybridizing conditions and identified as being homologous to the probe. Hybridization techniques are well known in the art. See, e.g., J. Sambrook, et al., supra, at Chapter 11.

The nucleic acid compounds of the present invention may also be used to hybridize to genomic DNA which has been digested with one or more restriction enzymes and run on an electrophoretic gel. The hybridization of radiolabeled probes onto such restricted DNA, usually fixed to a membrane after electrophoresis, is well known in the art. See, e.g., J. Sambrook, supra. Such procedures may be employed in searching for persons with mutations in these receptors by the well-known techniques of restriction fragment length polymorphisms (RFLP), the procedures of which are described in U.S. Patent 4,666,828, issued May 19, 1987, the entire contents of which is herein incorporated by reference.

- 40 -

The proteins of this invention as well as fragments of these proteins may be used as antigens for the synthesis of antibodies. The term "antibody" as used herein describes antibodies, fragments of antibodies (such as, but not
5 limited, to Fab, Fab', Fab₂', and Fv fragments), and chimeric, humanized, veneered, resurfaced, or CDR-grafted antibodies capable of binding antigens of a similar nature as the parent antibody molecule from which they are derived. The instant invention also encompasses single chain polypeptide binding
10 molecules.

The term "antibody" as used herein is not limited by the manner in which the antibodies are produced, whether such production is in situ or not. The term "antibody" as used in this specification encompasses those antibodies
15 produced by recombinant DNA technology means including, but not limited, to expression in bacteria, yeast, insect cell lines, or mammalian cell lines.

The production of antibodies, both monoclonal and polyclonal, in animals, especially mice, is well known in the art. See, e.g., C. Milstein, HANDBOOK OF EXPERIMENTAL IMMUNOLOGY,
20 (Blackwell Scientific Pub., 1986); J. Goding, MONOCLONAL ANTIBODIES: PRINCIPLES AND PRACTICE, (Academic Press, 1983). For the production of monoclonal antibodies the basic process begins with injecting a mouse, or other suitable animal, with
25 an immunogen. The mouse is subsequently sacrificed and cells taken from its spleen are fused with myeloma cells, resulting in a hybridoma that reproduces in vitro. The population of hybridomas is screened to isolate individual clones, each of which secretes a single antibody species, specific for the
30 immunogen. The individual antibody species obtained in this way is each the product of a single B cell from the immune animal generated in response to a specific antigenic site, or epitope, recognized on the immunogenic substance.

Chimeric antibodies are described in U.S. Patent
35 No. 4,816,567, which issued March 28, 1989 to S. Cabilly, et al. This reference discloses methods and vectors for the preparation of chimeric antibodies. The entire contents of

- 41 -

U.S. Patent No. 4,816,567 are herein incorporated by reference. An alternative approach to production of genetically engineered antibodies is provided in U.S. Patent No. 4,816,397, which also issued March 28, 1989 to M. Boss, et al., the entire contents of which are herein incorporated by reference. The Boss patent teaches the simultaneous co-expression of the heavy and light chains of the antibody in the same host cell.

The approach of U.S. Patent 4,816,397 has been further refined as taught in European Patent Publication No. 0 239 400, which published September 30, 1987. The teachings of this European patent publication (Winter) are a preferred format for the genetic engineering of the reactive monoclonal antibodies of this invention. The Winter technology involves the replacement of complementarity determining regions (CDRs) of a human antibody with the CDRs of a murine monoclonal antibody thereby converting the specificity of the human antibody to the specificity of the murine antibody which was the source of the CDR regions. This "CDR grafting" technology affords a molecule containing minimal murine sequence and thus is less immunogenic.

Single chain antibody technology is yet another variety of genetically engineered antibody which is now well known in the art. See, e.g., R.E. Bird, et al., Science 242:423-426 (1988); PCT Publication No. WO 88/01649, which was published 10 March 1988; United States Patent 5,260,203, issued November 9, 1993, the entire contents of which are herein incorporated by reference. The single chain antibody technology involves joining the binding regions of heavy and light chains with a polypeptide sequence to generate a single polypeptide having the binding specificity of the antibody from which it was derived.

The aforementioned genetic engineering approaches provide the skilled artisan with numerous means to generate molecules which retain the binding characteristics of the parental antibody while affording a less immunogenic format.

- 42 -

These antibodies are used in diagnostics, therapeutics or in diagnostic/therapeutic combinations. By "diagnostics" as used herein is meant testing that is related to either the in vitro or in vivo diagnosis of disease states or biological status in mammals, preferably in humans. By "therapeutics" and "therapeutic/diagnostic combinations" as used herein is respectively meant the treatment or the diagnosis and treatment of disease states or biological status by the in vivo administration to mammals, preferably humans, of the antibodies of the present invention. The antibodies of the present invention are especially preferred in the diagnosis and/or treatment of conditions associated with an excess or deficiency of human amyloid precursor protein proteases.

In addition to being functional as direct therapeutic and diagnostic aids, the availability of a family of antibodies which are specific for the human amyloid precursor protein protease enables the development of numerous assay systems for detecting agents which bind to this receptor. One such assay system comprises radiolabeling human amyloid precursor protein protease-specific antibodies with a radionuclide such as ^{125}I and measuring displacement of the radiolabeled human amyloid precursor protein protease-specific antibody from solid phase human amyloid precursor protein protease in the presence of a potential antagonist.

Numerous other assay systems are also readily adaptable to detect agents which bind human amyloid precursor protein protease. Examples of these aforementioned assay systems are discussed in Methods in Enzymology, (J. Langone. and H. Vunakis, eds. 1981), Vol. 73, Part B, the contents of which are herein incorporated by reference. Skilled artisans are directed to Section II of Methods in Enzymology, Vol. 73, Part B, supra, which discusses labeling of antibodies and antigens, and Section IV, which discusses immunoassay methods.

In addition to the aforementioned antibodies specific for the human amyloid precursor protein protease,

- 43 -

this invention also provides antibodies which are specific for the hypervariable regions of the anti-human amyloid precursor protein protease antibodies. Some such anti-idiotypic antibodies would resemble the original epitope, the
5 human amyloid precursor protein protease, and, therefore, would be useful in evaluating the effectiveness of compounds which are potential antagonists, agonists, or partial agonists of the human amyloid precursor protein protease. See, e.g., Cleveland, et al., Nature (London), 305:56 (1983);
10 Wasserman, et al., Proceedings of the National Academy of Sciences (USA), 79:4810 (1982).

In another embodiment, this invention encompasses pharmaceutical formulations for parenteral administration which contain, as the active ingredient, the anti-human
15 amyloid precursor protein protease antibodies described, supra. Such formulations are prepared by methods commonly used in pharmaceutical chemistry.

Products for parenteral administration are often formulated and distributed in solid, preferably freeze-dried
20 form, for reconstitution immediately before use. Such formulations are useful compositions of the present invention. Their preparation is well understood by pharmaceutical chemists.

In general, these formulations comprise the active
25 ingredient in combination with a mixture of inorganic salts, to confer isotonicity, as well as dispersing agents such as lactose, to allow the dried preparation to dissolve quickly upon reconstitution. Such formulations are reconstituted for use with highly purified water to a known concentration.

30 Alternatively, a water soluble form of the antibody can be dissolved in one of the commonly used intravenous fluids and administered by infusion. Such fluids include physiological saline, Ringer's solution or a 5% dextrose solution.

- 44 -

We Claim:

1. An isolated amino acid compound functional as a human amyloid precursor protein protease which comprises the amino acid sequence

5 Met Ala Arg Ser Leu Leu Leu Pro Leu Gln Ile Leu Leu Leu Ser Leu
1 5 10 15

10 Ala Leu Glu Thr Ala Gly Glu Glu Ala Gln Gly Asp Lys Ile Ile Asp
20 25 30

Gly Ala Pro Cys Ala Arg Gly Ser His Pro Trp Gln Val Ala Leu Leu
35 40 45

15 Ser Gly Asn Gln Leu His Cys Gly Gly Val Leu Val Asn Glu Arg Trp
50 55 60

Val Leu Thr Ala Ala His Cys Lys Met Asn Glu Tyr Thr Val His Leu
65 70 75 80

20 Gly Ser Asp Thr Leu Gly Asp Arg Arg Ala Gln Arg Ile Lys Ala Ser
85 90 95

25 Lys Ser Phe Arg His Pro Gly Tyr Ser Thr Gln Thr His Val Asn Asp
100 105 110

Leu Met Leu Val Lys Leu Asn Ser Gln Ala Arg Leu Ser Ser Met Val
115 120 125

30 Lys Lys Val Arg Leu Pro Ser Arg Cys Glu Pro Pro Gly Thr Thr Cys
130 135 140

Thr Val Ser Gly Trp Gly Thr Thr Thr Ser Pro Asp Val Thr Phe Pro
145 150 155 160

35 Ser Asp Leu Met Cys Val Asp Val Lys Leu Ile Ser Pro Gln Asp Cys
165 170 175

40 Thr Lys Val Tyr Lys Asp Leu Leu Glu Asn Ser Met Leu Cys Ala Gly
180 185 190

Ile Pro Asp Ser Lys Lys Asn Ala Cys Asn Gly Asp Ser Gly Gly Pro
195 200 205

45 Leu Val Cys Arg Gly Thr Leu Gln Gly Leu Val Ser Trp Gly Thr Phe
210 215 220

Pro Cys Gly Gln Pro Asn Asp Pro Gly Val Tyr Thr Gln Val Cys Lys
225 230 235 240

- 45 -

Phe Thr Lys Trp Ile Asn Asp Thr Met Lys Lys His Arg
245 250

5 which is SEQ ID NO:2, or a functional equivalent thereof, or
a fragment of at least 6 continuous amino acids thereof.

2. A nucleic acid compound encoding an amino acid
compound of Claim 1.

10

3. A composition comprising an isolated nucleic
acid compound containing a sequence encoding a human amyloid
precursor protein protease or fragment thereof as claimed in
Claim 2, wherein said sequence encoding a human amyloid
15 precursor protein protease or fragment thereof is selected
from the group consisting of:

(a) GAATTCGGTTT TTTT TTTT GAGGGTTT GTGTTT CT TTTATTTGTTTGGTTT TAGGTC
20 TTTACCAATTGATTGGTTTATCAACAGGGCATGAGGTTTAAATATATCTTTGAGGAAAG
GTAAAGTCAAATTTGACTTCATAGGTCATCGGCGTCCTCACTCCTGTGCATTTTCTGTTG
GAAGCACACAGTTAATTAACTCAGTGTGGCGTTAGCGATGCTTTTTCATGGTGTCAATTTA
25 TCCACTTGGTGAAC TTGCAGACTTGAGTGTAGACTCCTGGGTCATTGGGTTGGCCGCAAG
GGAAAGTTCCCCAGGACACCAGACCTTGAGGGTACCTCTGCACACCAACGGTCCCCCTG
AGTCACCATTCGAGGCGTTT TTTCTTGAGTCGGGGATGCCAGCGCACAGCATGGAATTTT
30 CCAGTAAGTCCTTGTAACCTTCGTGCAGTCCTGGGGGAGATGAGCTTGACATCCACGC
ACATGAGGTCAGAGGAAAGGTCACATCTGGGCTCGTGGTAGTGCCCCAGCCGGAGACAG
35 TACAGGTGGTTCCAGGGGTTTCGAGCGGGAGGGCAGCCTGACTTTCTTACCATGGATG
ACAGCCTGGCCTGGCTATTGAGCTTCACGAGCATGAGGTCATTAACATGGGTCTGTGTGG
40 AGTAGCCGGGGTGGCGGAATGACTTCGAGGCCTTGATCCTCTGAGCTCTCCTGTGCCCCA
GCGTATCACTGCCCAGGTGCACGGTGTACTCATTCATCTTGCACTGGGCGGCAGTGAGCA
CCCAGCGCTCATTGACCAGGACGCCTCCGCAGTGGAGCTGATTGCCACTGAGCAGGGCCA

- 46 -

CCTGCCATGGGTGGGAGCCTCTTGCACATGGGGCGCCATCAATAATCTTGTACCCCTGGG
CTTCTTCTCCTGCAGTTTCCAAGGCTAAGGATAGCAGTAAGATCTGCAGGGGCAGGAGAA
5 GGGATCTTGCCATGGTGCCCTGCTGAGCCGCTCAGGGGCTGCCAGGCGAGGAAGGGCCTC
TCCTGCTGGAGCTCGAGAGGATCTGATGTGATCCAAGTTCCGACTTGGGCTGGCACACAC
10 CGGAATTCC

which is SEQ ID NO:1;

(b) GAAUUCGGUUUUUUUUUUUGAGGGUUUGUGUUUCUUUAUUUGUUUUGGUUUUAGGUC
15 UUUACCAAUUUGAUUGGUUUAUCAACAGGGCAUGAGGUUUAAUAUAUCUUUGAGGAAAG
GUAAAGUCAAAUUUGACUUCAUAGGUCAUCGGCGUCCUCACUCCUGUGCAUUUUCUGUUG
20 GAAGCACACAGUUAUUAAUCUCAGUGUGGCGUUAGCGAUGCUUUUUCAUGGUGUCAUUUA
UCCACUUGGUGAACUUGCAGACUUGAGUGUAGACUCCUGGGUCAUUGGGUUGGCCGCAAG
GGAAAGUUCGCCAGGACACCAGACCUUGCAGGGUACCUCUGCACACCAACGGUCCCCCUG
25 AGUCACCAUUGCAGGCGUUUUUCUUGGAGUCGGGAUGCCAGCGCACAGCAUGGAAUUUU
CCAGUAAGUCCUUGUAAACCUUCGUGCAGUCCUGGGGGGAGAUGAGCUUGACAUCCACGC
30 ACAUGAGGUCAGAGGGAAAGGUCACAUCUGGGCUCGUGGUAGUGCCCCAGCCGGAGACAG
UACAGGUGGUUCCAGGGGGUUCGCAGCGGGAGGGCAGCCUGACUUUCUUCACCAUGGAUG
ACAGCCUGGCCUGGCUAUUGAGCUUCACGAGCAUGAGGUCAUUAACAUGGGUCUGUGUGG
35 AGUAGCCGGGUGGCGGAAUGACUUCGAGGCCUUGAUCCUCUGAGCUCUCCUGUCGCCCCA
GCGUAUCACUGCCCAGGUGCACGGUGUACUCAUUAUCUUGCAGUGGGCGGCAGUGAGCA
40 CCCAGCGCUCAUUGACCAGGACGCCUCCGCAGUGGAGCUGAUUGCCACUGAGCAGGGCCA
CCUGCCAUGGGUGGGAGCCUCUUGCACAUGGGGCGCCAUAUAUAUCUUGUCACCCUGGG
CUUCUUCUCCUGCAGUUUCCAAGGCUAAGGAUAGCAGUAAGAUCUGCAGGGGCAGGAGAA
45 GGAUCUUGCCAUGGUGCCCUGCUGAGCCGCUCAGGGGCGCCAGGCGAGGAAGGGCCUC
UCCUGCUGGAGCUCGAGAGGAUCUGAUGUGAUCCAAGUUCGACUUGGGCUGGCACACAC
50 CGGAATUCC

- 47 -

which is SEQ ID NO:3;

5 (c) a nucleic acid compound complementary to (a) or
(b); and

(d) a fragment of (a), (b), or (c) that are at least
18 bases in length and which will selectively
10 hybridize to human genomic DNA encoding an amyloid
precursor protein protease.

4. A composition as claimed in Claim 3 wherein the
isolated nucleic acid compound is deoxyribonucleic acid.

15 5. A composition as claimed in Claim 4 which is
(a) or a sequence complementary to (a).

6. A composition as claimed in Claim 2 wherein the
isolated nucleic acid compound is ribonucleic acid.

20 7. A composition as claimed in Claim 6 which is
(b) or a fragment thereof.

8. An expression vector capable of producing a
25 human amyloid precursor protein protease or a fragment
thereof in a host cell which comprises a nucleic acid
compound as claimed in Claim 3 in combination with regulatory
elements necessary for expression of the nucleic acid
compound in the host cell.

30 9. An expression vector as claimed in Claim 8
wherein the host cell is Escherichia coli.

- 48 -

10. An expression vector as claimed in Claim 8 wherein the host cell is a mammalian cell line.

11. An expression vector as claimed in Claim 8
5 which comprises the BK virus enhancer.

12. An expression vector as claimed in Claim 11 which further comprises an adenovirus late promoter.

13. A transfected host cell harboring an expression
10 vector as claimed in Claim 8.

14. A transfected host cell as claimed in Claim 13 which is Escherichia coli.

15. A transfected host cell as claimed in Claim 13 which is a mammalian cell line.

16. A transfected host cell as claimed in Claim 15
20 which is AV-12.

17. A method of evaluating the effectiveness of a test compound for the treatment or prevention of a condition associated with a deficiency of stimulation of a human
25 amyloid precursor protein protease which method comprises:

(a) introducing into a mammalian host cell an expression vector comprising DNA encoding a human amyloid precursor protein protease;
30

(b) culturing said host cell under conditions such that the human amyloid precursor protein protease is expressed;

- 49 -

- 5 (c) exposing said host cell expressing the human amyloid precursor protein protease to a test compound; and
- 10 (d) measuring the change in a physiological condition known to be influenced by the activity of the human amyloid precursor protein protease relative to a control in which the transfected host cell is not exposed to the test compound.

15 18. A method of evaluating the effectiveness of a test compound for use in the treatment or prevention of conditions associated with an excess or deficiency of stimulation of a human amyloid precursor protein protease comprising the steps of:

- 20 (a) isolating a human amyloid precursor protein protease;
- 25 (b) exposing said isolated human amyloid precursor protein protease to the test compound;
- 30 (c) exposing the isolated human amyloid precursor protein protease to a susceptible substrate simultaneously with or following the introduction of the test compound;
- (d) quantifying the concentration of susceptible substrate which has been proteolyzed; and

- 50 -

5 (e) comparing the concentration of said
proteolyzed susceptible substrate to a
control in which no test compound were
added.

19. A method of evaluating the effectiveness of a
test compound for use in the treatment or prevention of
conditions associated with an excess or deficiency of
10 stimulation of a human amyloid precursor protein protease
comprising the steps of:

15 (a) introducing into a mammalian host cell a
gene encoding an assayable gene product,
said gene containing a region suitable for
serving as a substrate for the human
amyloid precursor protein protease, said
assayable gene product having a different
phenotype depending on whether or not the
20 region suitable for serving as a substrate
for the human amyloid precursor protein
protease is cleaved or not;

25 (b) introducing into the mammalian host cell
of step (a) an expression vector
comprising DNA encoding a human amyloid
precursor protein protease;

30 (c) culturing said host cell under conditions
such that the human amyloid precursor
protein protease and the assayable gene
product are expressed;

- 51 -

- (d) exposing said host cell expressing the human amyloid precursor protein protease to a test compound; and
- 5 (e) assaying for the phenotype of the assayable gene product; and
- (f) comparing the phenotype of the assayable gene product to a control in which no test
10 compound is added.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/04294

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A01N 37/18, C12P 21/06, C07K 1/00, 14/00, 17/00

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/2; 435/240.2, 252.3, 219, 212, 69.1; 530/388.15, 350; 536/23.5, 23.2, 23.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	THE JOURNAL OF BIOLOGICAL CHEMISTRY. Volume 269, No. 30, Issued July 1994, Hansson et al., "Cloning, Expression, and Characterization of Stratum Corneum Chymotryptic Enzyme". Pages 19420-19426. Especially see page 19423, Fig.1 (100% amino acid sequence match with the claimed amino acid sequence) and discussion on page 19425, columns 2-3. Nucleotide sequence encoding stratum corneum chymotryptic enzyme showed 87% homology with the DNA sequence of the invention.	1-19

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T*	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be part of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

11 JUNE 1996

Date of mailing of the international search report

15 JUL 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer:

TEKCHAND SAIDHA

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/04294

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Nature, volume 331, issued February 1988, Kitaguchi et al., "Novel precursor of Alzheimers disease amyloid protein shows protease inhibitory activity", pages 530-532, especially see page 532, Fig.1, APP cDNA and the deduced amino acid sequence.	1-16
Y	Nature, volume 341, issued 14 September 1989, Oltersdcrf et al., "The secreted form of the Alzheimer's amyloid precursor protein with the Kunitz domain is protease nexin-II", pages 144-147, Fig.1. showing the deduced amino acid sequence of APP on page 145.	1
X, P	JOURNAL OF MEDICINAL CHEMISRTY, Volume 38, Number 21, issued 13 October 1995, "Therapeutic Approaches Related to Amyloid-beta Peptide and Alzheimer's Disease", pages 4141-4154, especially page 4143, column 2, lines 4-6 and last paragrapgh; page 4144 and future directions on page 4149-4150 and the references therein.	1-19
Y	US 5,220,013 A (P. A. PONTE et al.) 15 June 1993, columns 1-28.	1-19
Y, P	US 5,441,931 A (C.A.SPRECHER et al.) 15 August 1995, columns 1-24.	1-19

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/04294

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

514/2; 435/240.2, 252.3, 219, 212, 69.1; 530/388.15, 350; 536/23.5, 23.2, 23.1

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, MasPar (amino acid and nucleic acid sequence), STN (medline and Caplus).

Search Terms: Inventors name search; STN search Terms: human(amyloid or amyloid a4 or beta protein) and protease and amino acid sequence and DNA and treatment methods.

APS Search Terms: (Human or animal) and amyloid and precursor (protein or precursor protein) and protease and other related terms used.